BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Company News  |  Deals

MacroGenics, Eli Lilly deal

Lilly disclosed in its 4Q10 earnings that it notified MacroGenics of its decision to return exclusive, worldwide rights to develop and commercialize teplizumab. MacroGenics said Lilly returned teplizumab for commercial reasons. The biotech is evaluating teplizumab and its next-generation anti-CD3 compounds for Type I diabetes...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >